MariMed(OTC) MRMD

MariMed produces cannabis products for medical and recreational use. Its edibles and infused products offer alternatives to traditional medicines. The company serves patients, adult consumers, and retail partners seeking regulated cannabis solutions.

Products and Services

• Cannabis Flower & Concentrates:
• Infused Edibles: Chewable tablets and drink mixes (Kalm Fusion), and fruit chews (Betty's Eddies), for consumers seeking alternatives to smoking.
• Baked Goods: Brownies, cookies, and sweets (Bubby's Baked), targeting social and recreational users.
• Cannabidiol (CBD) Formulations: Florance brand, for those seeking non-psychoactive cannabis benefits.
• Licensing & Facility Leasing: Licenses brands and leases facilities to third parties, supporting industry partners.
• Wholesale Product Sales: Products are sold through wholesale channels, accounting for 43.2% of Q2 2025 revenue.

Growth and Expansion

• Acquired First State Compassion Center in Delaware in March 2025, expanding retail presence.
• Purchased Allgreens Dispensary (Illinois) and MedLeaf (Maryland) in 2024, increasing market reach.
• Entered management and licensing agreement with Standard Farms in Pennsylvania in September 2025.
• Expanded product lines and distribution through new dispensaries and wholesale channels since 2023.

What Makes MariMed Stand Out

MariMed controls its supply chain, from cultivation to retail sales. The company develops proprietary brands and licenses them to partners. Its strategy centers on acquisitions, product innovation, and expanding retail and wholesale networks.

Five Things You Need to Know

• Revenue was $40M in Q2 2025, down 2% from Q2 2024.
• Gross profit was $16M in Q2 2025, down 5.2% year-over-year.
• Retail sales accounted for 56.6% and wholesale for 43.2% of Q2 2025 revenue.
• Net loss improved to $-1M in Q2 2025, from $-2M in Q2 2024.
• Cash flow from operations was $297,000 in Q2 2025, down 90.7% year-over-year.

Bottom Line

MariMed has grown through acquisitions and product expansion, focusing on the U.S. cannabis market. The company balances retail and wholesale sales while navigating regulatory and operational challenges.